Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.

Burke PJ, Hamilton JZ, Pires TA, Setter JR, Hunter JH, Cochran JH, Waight AB, Gordon KA, Toki BE, Emmerton KK, Zeng W, Stone IJ, Senter PD, Lyon RP, Jeffrey SC.

Mol Cancer Ther. 2016 May;15(5):938-45. doi: 10.1158/1535-7163.MCT-16-0038. Epub 2016 Mar 4.

2.

Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation.

Okeley NM, Toki BE, Zhang X, Jeffrey SC, Burke PJ, Alley SC, Senter PD.

Bioconjug Chem. 2013 Oct 16;24(10):1650-5. doi: 10.1021/bc4002695. Epub 2013 Sep 19.

PMID:
24050213
3.

Development of orally active inhibitors of protein and cellular fucosylation.

Okeley NM, Alley SC, Anderson ME, Boursalian TE, Burke PJ, Emmerton KM, Jeffrey SC, Klussman K, Law CL, Sussman D, Toki BE, Westendorf L, Zeng W, Zhang X, Benjamin DR, Senter PD.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5404-9. doi: 10.1073/pnas.1222263110. Epub 2013 Mar 14.

4.

Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.

Burke PJ, Senter PD, Meyer DW, Miyamoto JB, Anderson M, Toki BE, Manikumar G, Wani MC, Kroll DJ, Jeffrey SC.

Bioconjug Chem. 2009 Jun;20(6):1242-50. doi: 10.1021/bc9001097.

PMID:
19469529
5.

Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.

Burke PJ, Toki BE, Meyer DW, Miyamoto JB, Kissler KM, Anderson M, Senter PD, Jeffrey SC.

Bioorg Med Chem Lett. 2009 May 15;19(10):2650-3. doi: 10.1016/j.bmcl.2009.03.145. Epub 2009 Apr 5.

PMID:
19386499
6.

Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).

Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, Liu A, Ueda R, Hodges D, Escandon E, Chen T, Kanavarioti T, Babé L, Senter PD, Fox JA, Schellenberger V.

Bioconjug Chem. 2006 Mar-Apr;17(2):410-8.

PMID:
16536473
7.

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF.

Cancer Res. 2006 Feb 15;66(4):2328-37.

8.

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.

Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD.

Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.

PMID:
16417259
9.

Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD.

Nat Biotechnol. 2003 Jul;21(7):778-84. Epub 2003 Jun 1.

PMID:
12778055
10.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF.

Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24.

PMID:
12714494
11.

Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs.

Toki BE, Cerveny CG, Wahl AF, Senter PD.

J Org Chem. 2002 Mar 22;67(6):1866-72.

PMID:
11895404
12.

Synthesis of the marine sponge cycloheptapeptide phakellistatin 5(1).

Pettit GR, Toki BE, Xu JP, Brune DC.

J Nat Prod. 2000 Jan;63(1):22-8.

PMID:
10650072
13.

Antineoplastic agents. 410. Asymmetric hydroxylation of trans-combretastatin A-4.

Pettit GR, Toki BE, Herald DL, Boyd MR, Hamel E, Pettit RK, Chapuis JC.

J Med Chem. 1999 Apr 22;42(8):1459-65.

PMID:
10212132

Supplemental Content

Support Center